ESR2 and prostate neoplasm: In addition, Apigenin was shown to inhibit the chymotrypsin activity of the proteasome, allowing a selective increase in the suppressor estrogen receptor-beta (ER-β) and triggering the extrinsic apoptotic pathway in prostate tumors in vitro and in vivo [192].